USClinicalTrials.govClinical trialPhase 3Active, not recruiting
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Official record
- Identifier
NCT03847428- Recruiting locations
countries
United StatesAustraliaAustriaBrazilCanadaChinaEgyptFranceGermanyHong KongIndiaItalyJapanPeruPhilippinesPolandPuerto RicoRussiaSingaporeSouth KoreaTaiwanThailandTurkey (Türkiye)Vietnam- Interventions studied
- DurvalumabBevacizumabPlacebo
- Lead sponsor
- AstraZeneca
- Target enrolment
- 908 participants
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Status
- Active, not recruiting
- First posted
- Feb 20, 2019
- Last updated on the registry
- Aug 14, 2026
- Age
- 18 Years – 150 Years
- Sex
- ALL
- Study contact
- No public contact is listed on the official record.
- Eligibility criteria
Reproduced verbatim from the official record. Eligibility is decided by the study team, never by this page.
Inclusion Criteria: * Histologically or cytologically (or radiologically for patients undergoing curative ablation), newly diagnosed, confirmed HCC and successfully completed curative therapy (resection or ablation) * Imaging to confirm disease-free status within 28 days prior to randomization * ECOG 0-1 at enrolment * Child-Pugh score of 5 or 6 * Adequate organ and marrow function. Exclusion Criteria: * Known fibrolamellar HCC, sarcomatoid HCC or mixed cholangiocarcinoma and HCC * Evidence of metastasis, macrovascular invasion or co-existing malignant disease on baseline imaging * History of hepatic encephalopathy within 12 months prior to randomization * Evidence, by Investigator assessment, of varices at risk of bleeding on upper endoscopy or contrast-enhanced cross-sectional imaging * Patients with Vp1 to Vp4 portal vein thrombosis on baseline imaging are excluded * Active co-infection with HBV and HDV. * Receipt of prior systemic anticancer therapy for HCC * Those on a waiting list for liver transplantation
- Indexed under
- Liver Cancer